AlzChem Group (ACT) 주식 개요
알츠켐 그룹은 자회사와 함께 독일, 유럽연합, 기타 유럽, 아시아, NAFTA 지역 및 국제적으로 다양한 화학 전문 제품을 개발, 생산 및 판매하고 있습니다. 자세히 보기
ACT Community Fair Values
Create NarrativeSee what 55 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Materials opportunity
ST
Fair Value from
CA$5.0768.0% 저평가 내재 할인율
An Undervalued 3.3Moz Gold Project in Canada
Key takeaways Upside Gold is developing the Kena Gold Project, near the town of Nelson in the Kootenays region of southern British Columbia. Kena hosts a historical gold resource of 3.33 million ounces (561,000 ounces Indicated and 2.77 million ounces Inferred) across a 10,200-hectare land package.
Read full narrativeAlzChem Group AG 경쟁사
가격 이력 및 성과
| 과거 주가 | |
|---|---|
| 현재 주가 | €163.80 |
| 52주 최고가 | €190.00 |
| 52주 최저가 | €115.80 |
| 베타 | 0.37 |
| 1개월 변동 | -10.59% |
| 3개월 변동 | 13.12% |
| 1년 변동 | 31.04% |
| 3년 변동 | 702.94% |
| 5년 변동 | 571.31% |
| IPO 이후 변동 | 509.15% |
최근 뉴스 및 업데이트
ACT: Specialty Chemicals Moat And 2026 Expansions Will Drive Future Upside
Narrative update on AlzChem Group The analyst fair value estimate for AlzChem has been lifted by €5 to €200, with analysts citing recent price target increases from multiple firms and reinforcing views around the company's specialty chemicals focus, margin profile and potential long term value creation. Analyst Commentary Bullish analysts have been steadily lifting their price targets for AlzChem, pointing to the specialty chemicals focus and the margin profile as key supports for higher valuations.
ACT: Specialty Platform And 2026 Expansions Will Underpin Cash Flow And Dividend Potential
Analysts have lifted their price targets on AlzChem to a range of about €195 to €197, reflecting updated models that incorporate a slightly lower discount rate, modestly higher revenue growth and profit margin assumptions, and a marginally reduced future P/E. Analyst Commentary Recent research points to a broadly constructive stance on AlzChem Group, with several firms lifting price targets into a narrow band between about €195 and €197.ACT: Specialty Platform And 2026 Expansions Will Support Measured Long Term Upside Potential
The updated analyst price target for AlzChem Group has moved from €165 to €173, as analysts point to recent target increases on the Street and renewed confidence in the company's specialty chemicals focus and niche production platform. Analyst Commentary Recent Street research has centered on higher price targets for AlzChem Group, with several firms highlighting the specialty chemicals profile and niche positioning as key supports for their views.Recent updates
ACT: Specialty Chemicals Moat And 2026 Expansions Will Drive Future Upside
Narrative update on AlzChem Group The analyst fair value estimate for AlzChem has been lifted by €5 to €200, with analysts citing recent price target increases from multiple firms and reinforcing views around the company's specialty chemicals focus, margin profile and potential long term value creation. Analyst Commentary Bullish analysts have been steadily lifting their price targets for AlzChem, pointing to the specialty chemicals focus and the margin profile as key supports for higher valuations.ACT: Specialty Platform And 2026 Expansions Will Underpin Cash Flow And Dividend Potential
Analysts have lifted their price targets on AlzChem to a range of about €195 to €197, reflecting updated models that incorporate a slightly lower discount rate, modestly higher revenue growth and profit margin assumptions, and a marginally reduced future P/E. Analyst Commentary Recent research points to a broadly constructive stance on AlzChem Group, with several firms lifting price targets into a narrow band between about €195 and €197.ACT: Specialty Platform And 2026 Expansions Will Support Measured Long Term Upside Potential
The updated analyst price target for AlzChem Group has moved from €165 to €173, as analysts point to recent target increases on the Street and renewed confidence in the company's specialty chemicals focus and niche production platform. Analyst Commentary Recent Street research has centered on higher price targets for AlzChem Group, with several firms highlighting the specialty chemicals profile and niche positioning as key supports for their views.
ACT: Specialty Chemicals Platform And 2026 Expansion Plans Will Support Upside
Analysts have lifted the implied fair value estimate for AlzChem Group to about €185 from roughly €177, supported by higher Street price targets in the €195 to €197 range and confidence in the company's specialty chemicals focus and production platform. Analyst Commentary Recent research updates point to a constructive tone from bullish analysts, who see the higher price targets as aligned with confidence in AlzChem Group's business model and execution around specialty chemicals.ACT: Specialty Chemicals Moat And 2026 Projects Will Drive Future Upside
Narrative Update on AlzChem Group The analyst price target for AlzChem Group has moved from €185 to €195, with analysts highlighting the company's specialty chemicals performance, unique production platform and high margin growth projects as key factors in their updated view. Analyst Commentary Bullish analysts are leaning into a constructive view on AlzChem Group, pointing to recent research updates as support for higher valuation expectations and confidence in the company’s execution.ACT: New Creatine Capacity Plan Will Support Measured Long Term Upside Potential
Analysts are holding their price target for AlzChem Group steady at €165.00. They explain the unchanged view by pointing to updated assumptions that combine a slightly higher discount rate and P/E multiple with adjusted revenue growth and profit margin expectations.ACT: New Creatine Investment Program Will Support Long Term Upside Potential
Analysts have lifted their price target on AlzChem Group from €150.00 to €165.00, citing updated assumptions around revenue growth, profit margins, and a lower future P/E multiple in their models. What's in the News AlzChem Group AG has approved an investment program of around €120 million aimed at supporting additional profitable growth and reinforcing its presence in specialty chemicals for sports, food, and health (company announcement).Is AlzChem Group AG (ETR:ACT) Trading At A 33% Discount?
Jan 23
ACT: New Creatine Plant And 2025 Outlook Will Underpin Balanced Prospects
Analysts have modestly trimmed their price target for AlzChem Group to €176.94 from €179.93 as minor adjustments to the discount rate, revenue growth assumptions, profit margin outlook and future P/E expectations feed into a slightly lower fair value estimate. What's in the News AlzChem Group AG approved an investment program of around €120 million to build a more automated production plant for creatine and its precursors, along with related infrastructure, targeting additional growth in sports, food and health (Key Developments).ACT: New Creatine Capacity Expansion And 2025 Record Outlook Will Support Upside
Analysts now set a higher fair value target for AlzChem Group at €179.93 compared with €167.10 previously. They point to updated assumptions for revenue growth, profit margins and a lower future P/E multiple.ACT: New Creatine Capacity And Partnerships Will Support Balanced Long Term Outlook
Analysts have raised their price target for AlzChem Group from €97.00 to €150.00, citing slightly stronger expectations for long term revenue growth and a higher justified future P E multiple, despite a modestly lower profit margin outlook. What's in the News AlzChem Group has approved an approximately EUR 120 million investment program to build a more automated creatine production plant and related infrastructure, targeting additional annual sales in the early triple-digit million euro range.ACT: Earnings Guidance And New Product Launch Will Drive Record Performance
Analysts have maintained their price target for AlzChem Group at €167.10. They cite steady outlooks for revenue growth and profit margins, with only minor adjustments to the discount rate and future earnings projections.AlzChem Group AG's (ETR:ACT) Business Is Trailing The Market But Its Shares Aren't
Nov 24ACT: Strong Revenue Outlook And Product Launches Will Drive Upside Momentum
Analysts have raised their price target for AlzChem Group from €163.10 to €167.10, citing improved revenue growth forecasts. These improved forecasts have offset slight adjustments in the discount rate and profit margin expectations.ACT: Profitability Improvements And Product Launch Partnerships Will Support Fair Valuation
Analysts have raised their price target for AlzChem Group from €154.24 to €163.10. They cite improved profit margin projections and continued confidence in the company's financial outlook.AlzChem Group AG (ETR:ACT) Shares Could Be 34% Below Their Intrinsic Value Estimate
Oct 13Is AlzChem Group (ETR:ACT) Using Too Much Debt?
Sep 13Global Nutrition Trends And Capacity Expansions Will Unlock Opportunities
The increase in AlzChem Group’s consensus price target is primarily driven by a higher forward P/E multiple rather than changes in revenue growth forecasts, with fair value rising from €135.24 to €143.64. What's in the News AlzChem Group AG confirmed its full-year 2025 guidance, projecting organic sales growth of approximately 5% to around EUR 580 million.Is Now An Opportune Moment To Examine AlzChem Group AG (ETR:ACT)?
Aug 20Global Nutrition Trends And Capacity Expansions Will Unlock Opportunities
AlzChem Group's higher consensus price target reflects improved profitability and a lower forward P/E, indicating stronger earnings expectations and valuation support, with fair value raised from €124.40 to €135.24. What's in the News AlzChem Group AG confirmed full year 2025 guidance, expecting approximately 5% organic sales growth to around EUR 580 million.AlzChem Group AG Just Missed Earnings And Its Revenue Numbers Were Weaker Than Expected
Aug 02AlzChem Group AG (ETR:ACT) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected
Jul 22Returns Are Gaining Momentum At AlzChem Group (ETR:ACT)
Jun 02A Look At The Fair Value Of AlzChem Group AG (ETR:ACT)
May 19What AlzChem Group AG's (ETR:ACT) 29% Share Price Gain Is Not Telling You
May 05AlzChem Group's (ETR:ACT) Dividend Will Be Increased To €1.80
May 03Is It Too Late To Consider Buying AlzChem Group AG (ETR:ACT)?
May 01AlzChem Group's (ETR:ACT) Dividend Will Be Increased To €1.80
Mar 28With EPS Growth And More, AlzChem Group (ETR:ACT) Makes An Interesting Case
Mar 18AlzChem Group AG (ETR:ACT) Just Reported And Analysts Have Been Lifting Their Price Targets
Mar 05AlzChem Group's (ETR:ACT) Dividend Will Be Increased To €1.80
Mar 03Market Still Lacking Some Conviction On AlzChem Group AG (ETR:ACT)
Feb 19
Expansion Of Nitroguanidine Production To Meet Defense Industry Demand Is Expected To Strengthen Market Position
Strategic expansion in production capacities and collaboration with the U.S. Department of Defense could bolster long-term revenue and market diversification.AlzChem Group's (ETR:ACT) Earnings May Just Be The Starting Point
Nov 14AlzChem Group AG's (ETR:ACT) Shares Leap 26% Yet They're Still Not Telling The Full Story
Oct 27When Should You Buy AlzChem Group AG (ETR:ACT)?
Oct 18AlzChem Group (ETR:ACT) Has A Pretty Healthy Balance Sheet
Sep 07A Look At The Intrinsic Value Of AlzChem Group AG (ETR:ACT)
Jun 04AlzChem Group's (ETR:ACT) Earnings Seem To Be Promising
May 08Shareholders Will Probably Hold Off On Increasing AlzChem Group AG's (ETR:ACT) CEO Compensation For The Time Being
May 01AlzChem Group's (ETR:ACT) Upcoming Dividend Will Be Larger Than Last Year's
Apr 26Is AlzChem Group (ETR:ACT) A Risky Investment?
Apr 11AlzChem Group's (ETR:ACT) Dividend Will Be Increased To €1.20
Mar 29The Market Lifts AlzChem Group AG (ETR:ACT) Shares 26% But It Can Do More
Mar 07주주 수익률
| ACT | DE Chemicals | DE 시장 | |
|---|---|---|---|
| 7D | -6.0% | -0.9% | -0.9% |
| 1Y | 31.0% | 5.5% | -0.9% |
수익률 대 산업: ACT은 지난 1년 동안 5.5%의 수익을 기록한 German Chemicals 산업보다 더 좋은 성과를 냈습니다.
수익률 대 시장: ACT은 지난 1년 동안 -0.9%를 기록한 German 시장보다 더 좋은 성과를 냈습니다.
주가 변동성
| ACT volatility | |
|---|---|
| ACT Average Weekly Movement | 6.2% |
| Chemicals Industry Average Movement | 5.7% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in DE Market | 12.3% |
| 10% least volatile stocks in DE Market | 2.6% |
안정적인 주가: ACT는 지난 3개월 동안 German 시장에 비해 주가 변동성이 크지 않았습니다.
시간에 따른 변동성: ACT의 주간 변동성(6%)은 지난 1년 동안 안정적이었습니다.
회사 소개
| 설립 | 직원 수 | CEO | 웹사이트 |
|---|---|---|---|
| 1908 | 1,680 | Andreas Niedermaier | www.alzchem.com |
알츠켐 그룹은 자회사와 함께 독일, 유럽연합, 기타 유럽, 아시아, NAFTA 지역 및 국제적으로 다양한 화학 전문 제품을 개발, 생산 및 판매하고 있습니다. 이 회사는 세 가지 부문으로 운영됩니다: 특수 화학, 기초 및 중간체, 기타 및 지주입니다. 특수 화학 부문은 화학, 식품, 동물 사료, 방위 기술 및 재생 에너지 산업에서 사용되는 특수 화학 제품을 판매합니다.
AlzChem Group AG 기초 지표 요약
| ACT 기초 통계 | |
|---|---|
| 시가총액 | €1.66b |
| 순이익 (TTM) | €66.82m |
| 매출 (TTM) | €581.10m |
24.8x
주가수익비율(P/E)2.9x
주가매출비율(P/S)ACT는 고평가되어 있습니까?
공정 가치 및 평가 분석 보기순이익 및 매출
| ACT 손익계산서 (TTM) | |
|---|---|
| 매출 | €581.10m |
| 매출원가 | €195.25m |
| 총이익 | €385.85m |
| 기타 비용 | €319.03m |
| 순이익 | €66.82m |
최근 보고된 실적
Mar 31, 2026
다음 실적 발표일
Jul 30, 2026
| 주당순이익(EPS) | 6.60 |
| 총이익률 | 66.40% |
| 순이익률 | 11.50% |
| 부채/자본 비율 | 14.3% |
ACT의 장기 실적은 어땠습니까?
과거 실적 및 비교 보기| AlzChem Group 배당 일정 | |
|---|---|
| 배당락일 | May 06 2026 |
| 배당 지급일 | May 08 2026 |
| 배당락일까지 남은 일수 | 0 days |
| 배당 지급일까지 남은 일수 | 2 days |
ACT는 안정적으로 배당을 지급합니까?
ACT 배당 기록 및 벤치마크 보기기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/05/05 03:22 |
| 종가 | 2026/05/05 00:00 |
| 수익 | 2026/03/31 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
AlzChem Group AG는 7명의 분석가가 다루고 있습니다. 이 중 6명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Volker Bosse | Baader Helvea Equity Research |
| Konstantin Wiechert | Baader Helvea Equity Research |
| Gerhard Orgonas | Berenberg |